Jan 21 2021 Read 877 Times
Thermo Fisher Scientific Inc and Groupe Novasep SAS have announced that Thermo Fisher has completed the acquisition of Henogen SA, Novasep’s viral vector manufacturing business in Belgium for approximately €725 million in cash.
Novasep’s viral vector manufacturing business provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Novasep’s viral vector business offers more than 7,000 m2 of state-of-the-art clinical and commercial manufacturing capacity. Founded more than 20 years ago, the business has approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and estimated 2020 revenue of €80 million (or approximately $95 million).
Thermo Fisher (TMO) Expands in Viral Vector With Henogen Buyout Zacks.com 1/18/2021
In an effort to expand its cell and gene vaccines and therapies footprint internationally,
Thermo Fisher Scientific Inc. TMO recently acquired Belgium-based Henogen S.A. Henogen is the viral vector manufacturing business of life sciences service and technology supplier, Groupe Novasep SAS.
Popular Searches
Per the financial terms of the deal, Thermo Fisher completed this acquisition for a deal value of approximately €725 million (roughly $880 million) in cash. This business will get integrated within Thermo Fisher’s Pharma Services business within the broader Laboratory Products and Services Segment.
A Glimpse of Henogen’s Business
Актуальные экономические, политические и финансовые новости. На сервере представлена информация о курсах валют и акций, экспресс-анализ ситуации на финансовых и товарных рынках; новости рынка ценных бумаг; исследования состояния отраслей российской экономики и промышленности.
Contract Manufacturers Archives - Pharmaceutical Business review pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
Lab equipment supplier Thermo Fisher said Friday that it coughed up €725 million ($876 million) in cash to purchase Henogen a company that makes viral vectors to deliver genetic material into cells from life science technology and services provider Novasep.